SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — May 1, 2013

ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: May 1, 2013 · CIK: 0001368514 · Accession: 0001193805-13-000874

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-186579

Date

May 1, 2013

Author

Brian Lenz

Form

CORRESP

Company

ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)

Letter

Re: ADMA Biologics, Inc. (the “Company”) Registration Statement on Form S-1, as amended

Unassociated Document

[ADMA Biologics, Inc. Letterhead]

May 1, 2013

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

File No. 333-186579

Ladies and Gentlemen:

Reference is made to the acceleration request letter (the “Acceleration Request”) filed on April 30, 2013 with the Securities and Exchange Commission by the Company with respect to the acceleration of the effective date of the above referenced Registration Statement. The Company hereby withdraws the Acceleration Request. The Company expects to file a new acceleration request in the future with a future requested effective date for the Registration Statement.

If you have any questions or comments, please do not hesitate to contact the undersigned or our counsel, Jeffrey A. Baumel or Roland S. Chase at (973) 912-7100.

Very truly yours,
ADMA BIOLOGICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

    Unassociated Document

[ADMA Biologics, Inc. Letterhead]

May 1, 2013

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re:
ADMA Biologics, Inc. (the “Company”)
Registration Statement on Form S-1, as amended

File No. 333-186579

Ladies and Gentlemen:

Reference is made to the acceleration request letter (the “Acceleration Request”) filed on April 30, 2013 with the Securities and Exchange Commission by the Company with respect to the acceleration of the effective date of the above referenced Registration Statement.  The Company hereby withdraws the Acceleration Request.  The Company expects to file a new acceleration request in the future with a future requested effective date for the Registration Statement.

If you have any questions or comments, please do not hesitate to contact the undersigned or our counsel, Jeffrey A. Baumel or Roland S. Chase at (973) 912-7100.

Very truly yours,

ADMA BIOLOGICS, INC.

/s/ Brian Lenz

Brian Lenz

Vice President and Chief Financial Officer

SecProbe.io